- Conditions
- Atrial Fibrillation
- Interventions
- Milvexian, Apixaban, Placebo, Apixaban Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20,284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 216
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Dothan, Alabama + 182 more
Recruitment Status
Active, not recruiting clinical trials
Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
10531
Shown on this page
12
Current sort
Recently updated
Status scope
Active, not recruiting
Additional filters apply within this recruitment status.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 577–588 of 10,531 matching trials with status Active, not recruiting.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Metastatic Prostate Cancer, Prostatic Neoplasms, Prostate Cancer, Prostatic Cancer, Prostate Neoplasms
- Interventions
- 18F-NaF, 18F-DCFPyL, 18F-FDG
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- SMARCB1-Deficient Malignancies, Epithelioid Sarcoma, Renal Medullary Carcinoma
- Interventions
- Ubamatamab, Cemiplimab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostatic Neoplasms, Adenocarcinoma
- Interventions
- JNJ-69086420, JNJ-78278343, Stereotactic body radiation therapy
- Drug · Radiation
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 8 more
- Conditions
- Gastroesophageal Reflux
- Interventions
- LINX Reflux Management System
- Device
- Lead sponsor
- Ethicon Endo-Surgery
- Industry
- Eligibility
- 21 Years to 99 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2032
- U.S. locations
- 21
- States / cities
- Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 18 more
- Conditions
- Castration-Resistant Prostatic Cancer
- Interventions
- Niraparib, Abiraterone Acetate, Prednisone, Placebo, New Formulation of Niraparib and Abiraterone Acetate (AA)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 765 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 47
- States / cities
- Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 40 more
- Conditions
- Multiple Myeloma
- Interventions
- JNJ-68284528, Lenalidomide, Daratumumab, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 33
- States / cities
- San Diego, California • San Francisco, California • New Haven, Connecticut + 27 more
- Conditions
- Arthritis, Psoriatic
- Interventions
- Icotrokinra, Placebo, Active reference comparator
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 552 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 9
- States / cities
- Jonesboro, Arkansas • DeBary, Florida • Plantation, Florida + 6 more
- Conditions
- Multiple Myeloma
- Interventions
- Cilta-cel, Talquetamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Iowa City, Iowa • Louisville, Kentucky • Detroit, Michigan + 2 more
- Conditions
- Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Laboratory Biomarker Analysis, Nab-paclitaxel, Questionnaire Administration
- Other · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 4
- States / cities
- Duarte, California • Lancaster, California • South Pasadena, California + 1 more
- Conditions
- Atopic Dermatitis
- Interventions
- APG777, Placebo
- Drug
- Lead sponsor
- Apogee Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 29
- States / cities
- Fountain Valley, California • Los Angeles, California • San Diego, California + 25 more
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma
- Interventions
- Ibrutinib, Venetoclax
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 32
- States / cities
- Cerritos, California • Los Alamitos, California • San Luis Obispo, California + 28 more